Nonbiopsy diagnosis of cardiac transthyretin amyloidosis

Circulation

Volumn 133, Issue 24, 2016, Pages 2404-2412

  Gillmore, Julian D ^a   Maurer, Mathew S ^b   Falk, Rodney H ^c   Merlini, Giampaolo ^d,e   Damy, Thibaud ^f   Dispenzieri, Angela ^g   Wechalekar, Ashutosh D ^a   Berk, John L ^h   Quarta, Candida C ^a   Grogan, Martha ^g   Lachmann, Helen J ^a   Bokhari, Sabahat ^b   Castano, Adam ^b   Dorbala, Sharmila ^c   Johnson, Geoff B ^g   Glaudemans, Andor W J M ⁱ   Rezk, Tamer ^a   Fontana, Marianna ^a   Palladini, Giovanni ^d,e   Milani, Paolo ^d,e   Guidalotti, Pierluigi L ^j,k   Flatman, Katarina ^a   Lane, Thirusha ^a   Vonberg, Frederick W ^a   Whelan, Carol J ^a   Moon, James C ^a   Ruberg, Frederick L ^h   Miller, Edward J ^l   Hutt, David F ^a   Hazenberg, Bouke P ⁱ   Rapezzi, Claudio ^j,k   Hawkins, Philip N ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NewYork Presbyterian Hospital   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f HENRI MONDOR HOSPITAL   (France)

^g MAYO CLINIC   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

amyloid; cardiomyopathies; genetics; hypertrophy; radionuclide imaging

Indexed keywords

3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; AMYLOID; BISPHOSPHONIC ACID DERIVATIVE; OXIDRONATE TECHNETIUM TC 99M; PROTEIN; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; PREALBUMIN;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; BONE SCINTISCANNING; CARDIAC TRANSTHYRETIN AMYLOIDOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEALTH CENTER; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; AMYLOID NEUROPATHIES, FAMILIAL; CLINICAL TRIAL; GENOTYPING TECHNIQUE; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PREALBUMIN;

EID: 84967240038     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.021612     Document Type: Article

References (36)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995; 32: 45-59
2. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003; 17: 909-927. doi: 10.1016/j.berh.2003.09.001
3. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012; 126: 1286-1300. doi: 10.1161/CIRCULATIONAHA.111.078915
4. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013; 2: e000098. doi: 10.1161/JAHA.113.000098
5. Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004; 30: 178-181. doi: 10.1002/dc.10370
6. Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014; 113: 1723-1727. doi: 10.1016/j.amjcard.2014.02.030
7. Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015; 128: 1275-1280. doi: 10.1016/j.amjmed.2015.05.039
8. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40: 232-239. doi: 10.1080/07853890701842988
9. Mirzoyev SA, Edwards WD, Mohammed SF, Donovan JL, Roger VL, Grogan DR, Redfield MM. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2010; 122: A17926
10. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112: 2047-2060. doi: 10.1161/CIRCULATIONAHA.104.489187
11. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014; 7: 552-562. doi: 10.1161/CIRCIMAGING.113.001396
12. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111: 186-193. doi: 10.1161/01.CIR.0000152819.97857.9D
13. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015; 132: 1570-1579. doi: 10.1161/CIRCULATIONAHA.115.016567
14. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC. Cardiovasc Imaging. 2014; 7: 133-142. doi: 10.1016/j. jcmg.2013.08.015
15. Pepys MB. Amyloidosis. Annu Rev Med. 2006; 57: 223-241. doi: 10.1146/annurev.med.57.121304.131243
16. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008; 14: 3219-3230
17. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013; 121: 3420-3427. doi: 10.1182/blood-2012-12-473066
18. Dubrey S, Ackermann E, Gillmore J. The transthyretin amyloidoses: advances in therapy. Postgrad Med J. 2015; 91: 439-448. doi: 10.1136/postgradmedj-2014-133224
19. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819-829. doi: 10.1056/NEJMoa1208760
20. Ali A, Turner DA, Rosenbush SW, Fordham EW. Bone scintigram in cardiac amyloidosis: a case report. Clin Nucl Med. 1981; 6: 105-108
21. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46: 1076-1084. doi: 10.1016/j.jacc.2005.05.073
22. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008; 51: 1509-1510. doi: 10.1016/j.jacc.2007.12.038
23. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011; 38: 470-478. doi: 10.1007/s00259-010-1642-7
24. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6: 195-201. doi: 10.1161/CIRCIMAGING.112.000132
25. Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Biagini E, Grigioni F, Bacchi-Reggiani ML, Lorenzini M, Milandri A, Branzi A, Rapezzi C. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012; 5: 755-758. doi: 10.1016/j.jcmg.2012.02.015
26. Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014; 21: 35-44. doi: 10.3109/13506129.2013.871250
27. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7: 157-165. doi: 10.1016/j. jcmg.2013.10.008
28. Castaño A, Bokhari S, Maurer MS. Unveiling wild-Type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36: 2595-2597. doi: 10.1093/eurheartj/ehv328
29. Tennent GA, Cafferty KD, Pepys MB, Hawkins PN. Congo red overlay immunohistochemistry aids classification of amyloid deposits. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. Pearl River, NY: Parthenon Publishing; 1999: 160-162
30. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114: 4957-4959. doi: 10.1182/blood-2009-07-230722
31. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001; 47: 673-680
32. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001; 97: 2900-2902
33. Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014; 35: E2403-E2412. doi: 10.1002/humu.22619
34. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013; 161: 525-532. doi: 10.1111/bjh.12286
35. Gillmore JD, Hawkins PN. V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015; 372: 1769. doi: 10.1056/NEJMc1503222#SA2
36. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014; 15: 1289-1298. doi: 10.1093/ehjci/jeu107